<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002063</url>
  </required_header>
  <id_info>
    <org_study_id>016A</org_study_id>
    <secondary_id>VA Study 298</secondary_id>
    <nct_id>NCT00002063</nct_id>
  </id_info>
  <brief_title>Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)</brief_title>
  <official_title>Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      Primary: To determine the clinical effect of zidovudine (AZT) compared to placebo in terms of&#xD;
      time to progression to AIDS (i.e., occurrence of major opportunistic infections, dementia,&#xD;
      and malignancies) or death. Initial drug assignment will be changed to open-label AZT for&#xD;
      patients who experience a sustained decline in CD4 lymphocyte concentration to less than 200&#xD;
      cells/mm3, but analysis will be based on initial treatment assignment. To determine the&#xD;
      immunologic effect of AZT compared to placebo in terms of time to drop in CD4 lymphocyte&#xD;
      concentration of at least 25 percent from baseline assessment. To determine the antiviral&#xD;
      effect of AZT compared to placebo in eradicating or suppressing HIV. Secondary: To determine&#xD;
      the effect of AZT compared to placebo on the immune status of HIV-infected patients by&#xD;
      comparing lymphocyte profiles and indices. To determine the long-term toxicities of AZT&#xD;
      compared to placebo in terms of abnormalities in BL, hepatic function, renal function, skin,&#xD;
      gastrointestinal system, and central nervous system. To describe the natural history of AIDS&#xD;
      related complex (ARC) in placebo patients in terms of initial CD4 lymphocyte concentration&#xD;
      and the Walter Reed staging system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patient must have AIDS related complex (ARC) as defined by Walter Reed stages, be&#xD;
        ambulatory, and be able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with unstable disease characterized by the following are excluded:&#xD;
&#xD;
          -  Hospitalization within the past 14 days.&#xD;
&#xD;
          -  Major opportunistic infection, current or past.&#xD;
&#xD;
          -  An active infection of onset during the past 30 days, as evidenced by symptoms, signs,&#xD;
             or laboratory abnormalities such as:&#xD;
&#xD;
          -  Temperature = or &gt; 100.5 degrees F.&#xD;
&#xD;
          -  Night sweats.&#xD;
&#xD;
          -  Weight loss = or &gt; 10 percent of body weight.&#xD;
&#xD;
          -  Diarrhea (3 or more bowel movements/day).&#xD;
&#xD;
          -  Persistent cough, shortness of breath, or dyspnea on exercise.&#xD;
&#xD;
          -  Abnormal chest x-ray suggesting pneumonia or increased arterial-alveolar (A-a)&#xD;
             gradient.&#xD;
&#xD;
          -  Altered mental status, seizures, or focal neurologic signs.&#xD;
&#xD;
          -  Abnormal computerized tomography (CT) scan or magnetic resonance imaging (MRI)&#xD;
             suggestive of toxoplasmosis, peripheral mononuclear leukocytes, lymphoma, or other&#xD;
             focal abnormality of the central nervous system (CNS).&#xD;
&#xD;
          -  Abnormal cerebrospinal fluid (CSF) suggestive of cryptococcal, mycobacterial, or other&#xD;
             meningitis. (The decision to perform invasive tests, such as lumbar puncture,&#xD;
             specialized microbiological tests such as bone marrow culture for Mycobacteria or&#xD;
             Histoplasma capsulatum, or specialized radiological tests such as CT scan or MRI&#xD;
             should be based on clinical assessment of the patient.)&#xD;
&#xD;
          -  Kaposi's sarcoma.&#xD;
&#xD;
          -  Lymphoma; malignancy requiring chemotherapy.&#xD;
&#xD;
          -  Dementia.&#xD;
&#xD;
          -  Requiring hemodialysis or renal insufficiency or failure.&#xD;
&#xD;
          -  Leukopenia.&#xD;
&#xD;
          -  Thrombocytopenia.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Unstable disease.&#xD;
&#xD;
          -  Kaposi's sarcoma.&#xD;
&#xD;
          -  Lymphoma; malignancy requiring chemotherapy.&#xD;
&#xD;
          -  Dementia.&#xD;
&#xD;
          -  Major opportunistic infection, current or past.&#xD;
&#xD;
          -  Anemia (hemoglobin less than 9.5 g/dl).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 1 month of study entry:&#xD;
&#xD;
          -  Ribavirin or zidovudine (AZT) or other antivirals.&#xD;
&#xD;
          -  Immunomodulating agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wadsworth Veterans Administration Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Veterans Administration Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>203075001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Gordon Dickinson</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Gigi Diamond / New York Veterans Administration</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Med Ctr / Admin Only / Not For Patient Care</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Veterans Administration Med Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 1990</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Immune Tolerance</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>AIDS-Related Complex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

